	US 12,240,827 B2
	Serotonin 5-HT2B inhibitory compounds
Richard Andrew Ewin, Kalamazoo, MI (US); Govindan Subramanian, Belle Mead, NJ (US); and Jinxia (Nancy) Deng, Portage, MI (US)
Assigned to Zoetis Services LLC, Parsippany, NJ (US)
Appl. No. 17/441,340
Filed by Zoetis Services LLC, Parsippany, NJ (US)
PCT Filed Mar. 26, 2020, PCT No. PCT/US2020/024969 § 371(c)(1), (2) Date Sep. 21, 2021, PCT Pub. No. WO2020/198478, PCT Pub. Date Oct. 1, 2020.
Claims priority of provisional application 62/825,051, filed on Mar. 28, 2019.
Prior Publication US 2022/0162183 A1, May 26, 2022
Int. Cl. C07D 401/12 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01)

CPC C07D 401/12 (2013.01) [C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01)]

7 Claims

1. A compound selected from the group consisting of:

(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone;

(4-(1H-imidazol-2-yl)piperidin-1-yl)(3′-chloro-[1,1′-biphenyl]-4-yl)methanone, trifluoroacetic acid salt; and

(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone;

and veterinary acceptable salts thereof.